Evidence map›Paper›PMID 38287365›Full record

ArticleMalaria journal2024

Molecular surveillance of Kelch 13 polymorphisms in Plasmodium falciparum isolates from Kenya and Ethiopia.

Brook Jeang, Daibin Zhong, Ming-Chieh Lee, Harrysone Atieli, Delenasaw Yewhalaw, Guiyun Yan

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Mapping Antimalarial Drug Resistance in Mozambique: A Systematic Review ofInternational journal of molecular sciences · 2024
    Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Global assessment of partial artemisinin resistance: multicenter trial across Kenya, Peru, and Thailand in patients with uncomplicated Plasmodium falciparum malaria.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Article
  17. Article
  18. Article
  19. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
  20. NovelAntimicrobial agents and chemotherapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Brook JeangProgram in Public Health, University of California Irvine, Irvine, CA, USA.
Daibin ZhongProgram in Public Health, University of California Irvine, Irvine, CA, USA.
Ming-Chieh LeeProgram in Public Health, University of California Irvine, Irvine, CA, USA.
Harrysone AtieliSchool of Public Health and Community Development, Maseno University, Kisumu, Kenya.
Delenasaw YewhalawSchool of Medical Laboratory Sciences, Faculty of Health Sciences, Jimma University, Jimma, Ethiopia.
Guiyun YanProgram in Public Health, University of California Irvine, Irvine, CA, USA. guiyuny@hs.uci.edu.
University of California, Irvine · USJimma University · ETMaseno University · KE

Funding

Vector Biology of Invasive Anopheles stephensi in Rural to Urban Landscapes in EthiopiaU19AI129326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Guiyun Yan · 2017 to 2026
$19.9M
Research Training in Mosquito Genomics and Bioinformat*D43TW001505 · FIC · UNIVERSITY OF CALIFORNIA-IRVINE · PI Guiyun Yan · 2000 to 2026
$6.0M
Epidemiology and Population Genetics of Malaria Parasites in KenyaF31AI164846 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI JEANG, BROOK · 2022 to 2024
$99k
FIC NIH HHS D43 TW001505FIC NIH HHS D43TW001505NIAID NIH HHS F31 AI164846NIAID NIH HHS U19 AI129326
6 · The paper itself

Abstract

backgroundTimely molecular surveillance of Plasmodium falciparum kelch 13 (k13) gene mutations is essential for monitoring the emergence and stemming the spread of artemisinin resistance. Widespread artemisinin resistance, as observed in Southeast Asia, would reverse significant gains that have been made against the malaria burden in Africa. The purpose of this study was to assess the prevalence of k13 polymorphisms in western Kenya and Ethiopia at sites representing varying transmission intensities between 2018 and 2022.

methodsDried blood spot samples collected through ongoing passive surveillance and malaria epidemiological studies, respectively, were investigated. The k13 gene was genotyped in P. falciparum isolates with high parasitaemia: 775 isolates from four sites in western Kenya (Homa Bay, Kakamega, Kisii, and Kombewa) and 319 isolates from five sites across Ethiopia (Arjo, Awash, Gambella, Dire Dawa, and Semera). DNA sequence variation and neutrality were analysed within each study site where mutant alleles were detected.

resultsSixteen Kelch13 haplotypes were detected in this study. Prevalence of nonsynonymous k13 mutations was low in both western Kenya (25/783, 3.19%) and Ethiopia (5/319, 1.57%) across the study period. Two WHO-validated mutations were detected: A675V in three isolates from Kenya and R622I in four isolates from Ethiopia. Seventeen samples from Kenya carried synonymous mutations (2.17%). No synonymous mutations were detected in Ethiopia. Genetic variation analyses and tests of neutrality further suggest an excess of low frequency polymorphisms in each study site. Fu and Li's F test statistic in Semera was 0.48 (P > 0.05), suggesting potential population selection of R622I, which appeared at a relatively high frequency (3/22, 13.04%).

conclusionsThis study presents an updated report on the low frequency of k13 mutations in western Kenya and Ethiopia. The WHO-validated R622I mutation, which has previously only been reported along the north-west border of Ethiopia, appeared in four isolates collected from eastern Ethiopia. The rapid expansion of R622I across Ethiopia signals the need for enhanced monitoring of the spread of drug-resistant P. falciparum parasites in East Africa. Although ACT remains currently efficacious in the study areas, continued surveillance is necessary to detect early indicators of artemisinin partial resistance.

Indexed as

AntimalarialsArtemisininsMalaria, FalciparumAntiparasitic AgentsDrug ResistanceEthiopiaHumansKenyaMutationPlasmodium falciparumProtozoan ProteinsAntimalarialsAntiparasitic AgentsartemisininArtemisininsProtozoan ProteinsAfricaArtemisinin resistanceMalariaPlasmodium falciparum

Identifiers

PMID38287365
PMCPMC10823687
OpenAlexW4391304211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.